Figure 11.

Expression levels of STING and IFNβ in a CT26 syngeneic animal model after monotherapy or combination of midostaurin (PKC412) and anti-PD-1. At the end of the experiment, mice were sacrificed and tumor specimens were harvested for immunohistochemistry staining STING (a) and IFNβ (b) protein expressions. The score of STING and IFNβ protein expressions level in tumor (c) after tumor cells implanted in syngeneic BALB/c mice. Data from six mice of each group were expressed as mean ± SEM. Significant differences between control group and PKC412-treated group, or anti-PD-1-treated group and combination-treated group are indicated by * p < 0.05, ** p < 0.01.